Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study
Why the study?
Are baseline levels of advanced glycation end products associated with coronary plaque progression in patients with acute coronary syndrome receiving statin therapy?
Population
208 patients with acute coronary syndrome who underwent intravascular ultrasound-guided percutaneous…
Design
Cohort
Follow-up
8-12 months
Authors
Discussion
Loading...
Member takes
Implication
May identify higher-risk statin-treated ACS patients; leaves open whether AGEs are modifiable targets for plaque stabilization.
Structured PICO
Are baseline levels of advanced glycation end products associated with coronary plaque progression in patients with acute coronary syndrome receiving statin therapy?
P
Population
208 patients with acute coronary syndrome (ACS) who underwent intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI)
I
Intervention
Statin treatment (pitavastatin 4 mg/day or atorvastatin 20 mg/day)
O
Outcome
Coronary plaque volume (PV) progression in non-culprit segments measured by IVUS and its association with serum levels of advanced glycation end products (AGEs) and soluble RAGE (sRAGE) at 8-12 monthssurrogate
High baseline levels of advanced glycation end products independently predict coronary plaque progression in ACS patients undergoing PCI and statin therapy, suggesting a role for oxidative stress beyond diabetes.
Cite This Study
Fukushima et al. (2013) studied this question.